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Abstract
Honokiol (HNK) is a phenolic compound isolated from the bark of houpu (Magnolia
officinalis), a plant widely used in traditional Chinese and Japanese medicine. While
substantial evidence indicates that HNK possesses anti-inflammatory activity, its effect
on dendritic cells (DCs) during the inflammatory reaction remains unclear. The present 
study investigates how HNK affects lipopolysaccharide (LPS)-stimulated human
monocyte-derived DCs. Our experimental results show that HNK inhibits the 
inflammatory response of LPS-induced DCs by (1) suppressing the expression of 
CD11c, CD40, CD80, CD83, CD86, and MHC-II on LPS-activated DCs, (2) reducing 
the production of TNF-D, IL-1E, IL-6, and IL-12p70 but increasing the production of 
IL-10 and TGF-E1 by LPS-activated DCs, (3) inhibiting the LPS-induced DC-elicited 
allogeneic T-cell proliferation, and (4) shifting the LPS-induced DC-driven Th1 
response toward a Th2 response. Further, our results show that HNK inhibits the 
phosphorylation levels of ERK1/2, p38, JNK1/2, IKKD, and INBD in LPS-activated
DCs. Collectively, the findings show that the anti-inflammatory actions of HNK on 
LPS-induced DCs are associated with the NF-NB and mitogen-activated protein kinase
(MAPK) signaling pathways. 
Introduction
For thousands of years, herbal medicine has been used for the treatment of many
diseases. Houpu (Magnolia officinalis) is an important medicinal herb widely used to 
treat fever, headache, anxiety, and nervous disturbance in Chinese and Japanese 
medicine (Squires et al., 1999). Honokiol (HNK, C18H18O2, MW=266.33) is an active
compound isolated from the houpu (Liou et al., 2003b; Watanabe et al., 1983). HNK 
has been reported to have several pharmacological functions, including 
anti-inflammatory (Chiang et al., 2009; Lee et al., 2005; Liou et al., 2003a; Munroe et
al., 2007), anti-oxidant (Dikalov et al., 2008; Lo et al., 1994), anti-bacterial (Park et al., 
2004), and apoptotic functions (Ahn et al., 2006; Yang et al., 2002). It also inhibits 
cancer cell proliferation, both in vitro (Battle et al., 2005; Ishitsuka et al., 2005; Tse et 
al., 2005; Yang et al., 2002) and in vivo (Bai et al., 2003). 
Dendritic cells (DCs) are considered to be the principal antigen-presenting cells, 
and they play a prominent role in the development of T-cell immune responses 
(Banchereau et al., 2000; Banchereau and Steinman, 1998). The development of DCs 
comprises two functional stages. Immature DCs are primarily localized in the 
peripheral tissues. Their main function is antigen phagocytosis and processing. 
Following antigen uptake, DCs migrate to the lymphoid organs, where they become
potent antigen presenters and thereby activate T cells (Cella et al., 1997b). The
maturation of DCs is critical to initiate the adaptive immune response since fully 
mature DCs can induce antigen-specific T-lymphocyte responses and control the 
differentiation of T cells toward Th1 or Th2 immunity (Abbas et al., 1996; Seder and 
Paul, 1994). Fully mature DCs exhibit high surface expression of MHC-II and
costimulatory molecules such as CD40, CD80, and CD86 (Chambers and Allison,
1999; Quah and O'Neill, 2005) but decreased capacity to internalize antigens (Cella et 
al., 1997a; Lin et al., 2005). Additionally, CD83, a specific marker of DC maturation,
is upregulated (Reddy et al., 1997). The expression of MHC-II, CD40, CD80, and 
CD86 on DCs is essential for T-lymphocytes activation (Banchereau and Steinman,
1998; Lechmann et al., 2001). The integrin CD11c is known as a marker of DCs and 
has been proposed to function in phagocytosis, cell migration, cytokine production, 
and inflammation (Georgakopoulos et al., 2008; Sadhu et al., 2007). Many stimuli are 
able to induce DC maturation, including proinflammatory cytokines, the CD40 ligand, 
and pathogen–associated materials such as lipopolysaccharide (LPS), bacteria DNA, 
and the unmethylated DNA CpG motif (Banchereau et al., 2000). 
Toll like receptors (TLRs) recognize conserved structural motifs on 
microorganisms known as pathogen-associated molecular patterns (PAMPs). LPS, an
integral component of the outer membrane of gram-negative bacteria, can trigger an 
acute inflammatory response, leading to a series of pathological events such as septic
shock (Martich et al., 1993). DCs play an important role in the elimination of
pathogens and provide a link between innate and adaptive immunity (Banchereau et al., 
2000; Banchereau and Steinman, 1998). They are extremely sensitive to even low 
concentration of LPS and respond to this cue by releasing inflammatory mediators
(Verhasselt et al., 1997). DC activation by LPS eventually triggers an antigen-specific 
T-cell response (Rieser et al., 1998). Briefly, LPS is a potent activator of DCs and 
triggers the production of proinflammatory cytokines such as IL-1, IL-6, TNF-D, and 
IL-12 and promotes DC maturation via the TLR4 signaling pathway (de Jong et al., 
1999; Kelleher and Beverley, 2001; Roake et al., 1995), which in turn triggers the
signaling cascades that result in the activation of NF-NB and mitogen-activated protein 
kinase (MAPK) (Akira and Takeda, 2004). 
Previous reports have demonstrated that HNK has anti-inflammatory effects,
whereby it inhibits reactive oxygen species-related inflammatory responses in 
neutrophils by inhibiting the activity of NADPH oxidase, myeloperoxidase, and 
cyclooxygenase, and subsequently enhancing the GSH activity (Liou et al., 2003b). 
Moreover, Lee et al. showed that HNK has an antioxidant effect, whereby it reduces 
the production of IL-8 and TNF-D, and inhibits the activation of NF-NB in 
Propionibacterium acnes-activated THP-1 cells (Lee et al., 2005). Munroe et al.
demonstrated that HNK prevents the flare up of symptomatic collagen-induced
arthritis in both CD40-LMP1 transgenic mice and their congenic C57BL/6 
counterparts and inhibits CD40- and latent membrane protein-1 (LMP1)-mediated
B-cell activation by abrogating the activation of NF-NB and AP-1, and inhibiting the 
production of TNF-D and IL-6 (Munroe et al., 2007). However, to date, no studies have 
reported the effects of HNK on the functions of DCs. In the present study, 
LPS-activated DCs were used as a model of the inflammatory stage to investigate
whether HNK affects the LPS-induced inflammatory response. 
Materials and methods 
Reagents
HNK (purity > 98%) was purchased from Wako Pure Chemical Industries, Ltd. (Osaka,
Japan). The HNK contained less than 0.01 EU/ml LPS as measured using the Limulus 
Amoebocyte Lysate (LAL) Chromogenic Endpoint assay (Hycult Biotech, Uden, the 
Netherlands) (data not shown). The culture medium used in this study was RPMI 1640 
(Gibco-BRL, Life Technologies, Paisley, UK) supplemented with 2 mM L-glutamine,
25 mM HEPES, 100 U/ml penicillin, 0.1 mg/ml streptomycin (Gibco-BRL, Life
Technologies, Paisley, UK), and 10% heat-inactivated FCS (Hyclone, Logan, UT, 
USA). Recombinant human GM-CSF, recombinant human IL-4, and human soluble 
CD40 ligand (sCD40L) were purchased from PeproTech (Rocky Hill, NJ, USA). LPS
(Escherichia coli serotype O55:B5), MTT, BSA, DMSO, proteinase K, FITC-dextran 
(40,000 Da), FITC-LPS, and lucifer yellow were purchased from Sigma (St. Louis, 
MO, USA). FITC-E. coli was purchased from Orpegen Pharma (Heidelberg, 
Germany). Mouse anti-human mAbs conjugated with FITC or PE were used to detect
CD4, CD11c CD14, CD25, CD40, CD80, CD83, CD86, HLA-DR, and FoxP3. All
mAbs and isotype control Abs were purchased from eBioscience (San Diego, CA, 
USA). ELISA kits for detection of human TNF-D, IL-1E, IL-4, IL-6, IL-10, IL-12p70, 
IL-13, IL-17, TGF-E1, and IFN-J were also purchased from eBioscience (San Diego, 
CA, USA). For intracellular staining, Brefeldin A, fixation buffer, permeabilization
buffer, FITC-labeled anti-human IFN-J mAb, and PE-labeled anti-human IL-4 mAb 
were purchased from eBioscience (San Diego, CA, USA). Cell proliferation was
measured by using the BrdU ELISA kit that was purchased from Roche Molecular
Biochemicals (Mannheim, Germany). For Western blot analysis, we used anti-ERK1 
rabbit polyclonal IgG (Santa Cruz, CA, USA; catalog No. sc-94), anti-JNK1 rabbit 
polyclonal IgG (Santa Cruz; catalog No. sc-474), anti-p38 rabbit polyclonal IgG (Santa 
Cruz; catalog No. sc-535), monoclonal anti-MAP kinase, activated (diphosphorylated 
ERK-1&2) IgG1 (Sigma-Aldrich, St. Louis, MO, USA; catalog no. M9692), 
monoclonal anti-JNK, activated (diphosphorylated JNK) IgG1 (Sigma-Aldrich;
catalog no. J4750), monoclonal anti-p38 MAP kinase, activated (diphosphorylated p38) 
IgG1 (Sigma-Aldrich; catalog no. M8177), anti-phospho-INBD (Ser32/Ser36) rabbit 
polyclonal IgG (Millipore, Billerica, MA, USA; catalog No. 07-836), anti-INBD mouse
monoclonal IgG1 (Santa Cruz; catalog No. sc-1643) anti-phospho-IKKD
(Ser176/Sser180) rabbit polyclonal IgG (Millipore; catalog No. 07-837), and 
anti-IKKD mouse monoclonal IgG1 (Millipore; catalog No. 05-536). The human
specific TLR9 ligand (CpG oligodeoxynucleotides (CPG ODNs)-Type A) was 
purchased from Invivogen (San Diego, CA, USA). 
Generation of human monocyte-derived DCs 
The detailed experimental procedure for generating monocyte-derived DCs was as
described previously (Li et al., 2009). Briefly, whole blood samples from healthy 
volunteers were obtained from the Taipei Blood Center by an Institutional Review 
Board (IRB) approved procedure issued by Academia Sinica, Taipei, Taiwan. PBMCs 
were separated from the whole blood by using Ficoll-Hypaque density gradient 
centrifugation and then monocytes were isolated by the plastic adherence method
(Thurner et al., 1999). The purity of the monocyte population was >90% as assessed by 
CD14 staining (data not shown). Immature DCs were generated from monocytes that
were cultured for 6 days at 37°C in an incubator with 5% humidified CO2 in RPMI 
1640 culture medium supplemented with 500 U/ml recombinant human GM-CSF and 
1000 U/ml recombinant human IL-4. On days 2 and 4, half the medium was replaced 
with fresh medium containing recombinant human GM-CSF and recombinant human
IL-4.
Cell culture and cell viability assay 
HNK was dissolved in DMSO at a stock concentration of 100 mg/ml. It was further 
diluted in the culture medium at a final DMSO concentration of <0.02%. In order to 
minimize the effects of proteins and peptidoglycan contamination in our studies, the 
contaminating proteins and peptidoglycan in the LPS sample were removed by 
proteinase K treatment (300 µg/ml) before the experiments. Then, the proteinase K 
was also removed by dialysis, and the purity of the LPS sample was determined by 
NMR spectroscopy (data not shown). On day 6 of DC culture, a total of 10
6
immature
DCs were reseeded into a 6-well culture plate and treated with HNK at various 
concentrations (0, 5, 10, 15, and 20 µg/ml) in a culture for 2 days. LPS-, CpG ODNs-, 
and sCD40L-activated DCs were generated from immature DCs by culturing for 2 
days in the presence of LPS (1 µg/ml), CpG ODNs (10 µg/ml), and sCD40L (1 µg/ml),
respectively, and HNK at various concentrations (0, 5, 10, 15, and 20 µg/ml). The
untreated controls (HNK, 0 µg/ml, LPS alone, CpG ODNs alone, or sCD40L alone) 
were treated with 0.02% DMSO as the vehicle control. The viability of the cells 
following these treatments was determined by the MTT assay that was performed
following the manufacturer’s instructions (Sigma, St. Louis, MO, USA). 
Phenotypic characterization of DCs 
For phenotypic analysis of DCs, the cells were incubated with FITC- or PE-labeled
mAbs against human CD11c, CD14, CD40, CD80, CD83, CD86, or HLA-DR or
isotype control Abs for 40 min at 4°C. The cells were then washed twice with cold
PBS containing 2% FCS and analyzed by flow cytometry (Partec, Munster, Germany).
For each analysis, 20,000 cells were acquired by flow cytometry and analyzed using 
WinMDI software (Scripps, La Jolla, CA, USA). CD14 is a monocyte lineage specific 
marker, and was not presented on the DC surface (data not shown). All assays were 
performed in triplicate. 
Analysis of endocytic activity 
The phagocytic activity of DCs was measured as described previously with slight 
modification (Duperrier et al., 2000). Briefly, a total of 5 × 10
5
DCs were resuspended 
in 100 µl PBS containing 2% FCS and then incubated with FITC-dextran (0.1 mg/ml),
FITC-E. coli (40:1, E. coli:DC ratio), or lucifer yellow (1 mg/ml) at 37°C for 30 min.
Following incubation, the cells were washed four times in cold PBS that contained 2% 
FCS and analyzed by flow cytometry. As a control, cells cultured under each condition
were left untreated in the same solution for 30 min at 4°C. All assays were performed
in triplicate. 
Allogeneic MLR assay 
For the MLR assay, responder cells (T cells) were obtained from allogeneic PBMCs by 
nylon wool column purification (Polysciences, Warrington, PA, USA). The purity of 
CD3-positive T cells was shown to be at least 85%, as determined by flow cytometry
(data not shown). Immature DCs treated for 2 days with HNK, LPS, or a combination
of LPS and HNK were used as the stimulator cells. Before the MLR experiment, the
DCs were washed twice with HBSS. In the flat-bottomed 96-well plates containing 0.2 
ml medium per well, 2 × 10
3
stimulator cells were cocultured for 3 days with a graded
ratio of responder cells (1:25, 1:50, 1:75, and 1:100). Allostimulatory activity was 
measured following the addition of 10 µM BrdU during the last 14 h of the 3-day 
culture period. Proliferation of T cells was determined by measuring BrdU 
incorporation with the cell proliferation ELISA kit according to the manufacturer’s
instructions (Roche Molecular Biochemicals, Mannheim, Germany). All assays were 
performed in triplicate. 
Measurement of cytokine secretion 
DC supernatants were harvested after 2 days of incubation with medium alone, LPS, or
a combination of LPS and HNK. TNF-D, IL-1E, IL-6, IL-10, IL-12p70, and TGF-E1
levels in DC supernatants were quantified using ELISA kits (eBioscience, San Diego, 
CA, USA). T cells were cocultured with LPS-treated, or a combination of LPS and 
HNK-treated DCs for 3 days. To assess the T cell differentiation, the levels of IFN-Ȗ,
IL-4, IL-10, IL-13, and IL-17 in the supernatant were measured by ELISA and 
normalized to total cell numbers at the end of the treatment. Cell viability was
measured by the MTT assay. For intracellular staining, cells were fixed with a fixation
buffer for 30 min and permeabilized with permeabilization buffer for 30 min as per the 
manufacturer’s instructions (eBiosciences, San Diego, CA, USA). Cells were stained 
with FITC-labeled anti-IFN-J and PE-labeled anti-IL-4 mAb (eBiosciences, San Diego,
CA, USA) and analyzed by flow cytometry (Partec, Munster, Germany). All assays
were performed in triplicate. 
LPS binding assay 
The methods for the LPS binding assay were as described previously (Yuan et al., 
2009). In brief, immature DCs were treated at 37°C for 30min with 1 µg/ml
FITC-labeled LPS (FITC-LPS) and HNK at various concentrations (0, 10, and 20
µg/ml). They were then washed with HBSS for three times. The FITC-LPS binding
assay was analyzed by flow cytometry.
Western Blot 
To investigate the phosphorylation levels of ERK1/2, JNK1/2, p38, IKKD, and INBD,
immature DCs were treated with LPS (1 µg/ml) in the presence or absence of 20 µg/ml
HNK for 15, 30, 60, and 120 min. After stimulation, the cells were washed twice with 
PBS and lysed with lysis buffer. Whole cell lysates were separated by 10% SDS gel 
electrophoresis and electrotransferred to polyvinylidene difluoride membranes (Pall 
Corporation, East Hills, NY, USA). The membranes were incubated in blocking
solution (5% nonfat milk in PBS with 0.1% Tween 20) at room temperature for 1 h. 
They were then incubated with specific primary antibodies (1:1000 diluted in blocking 
solution) for 2 h, washed, and incubated with a HRP-conjugated secondary antibody 
(1:2000 diluted in blocking solution) to the primary antibody. The membranes were 
developed using an ECL Western blotting detection system (Pierce Corporation, 
Rockford, IL, USA). The bands were quantified using AlphaImage software (Alpha 
Innotech Corporation, San Leandro, CA, USA). The relative fold of phosphorylation 
activity each time was normalized to that of the unphosphorylated form and then 
compared to each untreated control group. 
Statistical analysis 
All assays were performed as at least 3 independent experiments using different donors. 
The results are presented as the mean ± SD of the repeated experiments and were
analyzed using SPSS software (SPSS Inc., Chicago, Illinois, USA). Data were 
compared between control and treatment groups by using Student’s t-test. Differences
were regarded as statistically significant for P values of less than 5% (p < 0.05) and 1% 
(p < 0.01). 
Results
Dose ( 20 µg/ml) of HNK does not affect DC survival 
The goal of this study was to investigate the effect of HNK on the immunomodulating
functions of DCs. Considering that human monocyte-derived DCs are normal immune
cells, the dosage of HNK used in this study should not affect their survival. To examine
the toxicity of HNK, immature DCs were treated with HNK at various concentrations 
(0, 5, 10, 15, and 20 µg/ml) in the absence or presence of LPS (1 µg/ml) for 2 days. 
Cell viability was analyzed by the MTT assay. The results revealed that the cell
survival rate did not differ significantly when the DCs were treated with  20 µg/ml
HNK (Fig. 1). At these HNK concentrations, even the presence of LPS at 1 µg/ml did 
not significantly affect the DC survival rate (Fig. 1). However, HNK was toxic to the 
DCs at concentrations of  50 µg/ml (Fig. 1). The maximum dose used in the following 
experiments is 20 µg/ml HNK. 
HNK inhibits phenotypic maturation of LPS-activated DCs 
To investigate the effects of HNK on DC maturation, immature DCs were treated for 2 
days with HNK at various concentrations (0, 10, and 20 µg/ml) in the absence or
presence of LPS (1 µg/ml), which induces inflammation and promotes DC maturation 
(de Jong et al., 1999; Kelleher and Beverley, 2001; Roake et al., 1995). The expression 
of surface molecules (CD11c, CD40, CD80, CD83, CD86, and MHC-II) was
examined by flow cytometry. The results showed that HNK suppressed the 
LPS-induced expression of CD11c, CD40, CD80, CD83, CD86, and MHC-II by DCs 
(Fig. 2 and Table 1). In the control group, HNK inhibited the expression of CD11c,
MHC-II and costimulatory molecules (CD40, CD80, and CD86) by immature DCs,
but its effects were less intense than those on LPS-stimulated DCs (Fig. 2 and Table 1). 
HNK impairs endocytic activity in both immature DCs and LPS-activated DCs 
Endocytosis is a process of antigen uptake, which is mediated by receptors such as the 
mannose receptor and Fc gamma receptor, whereby antigens and immune complexes
are internalized (Huang et al., 2006; Lin et al., 2005). To examine whether HNK 
affects the endocytic activity of DCs, immature DCs generated from human monocytes
were treated with HNK at various concentrations (0, 10, and 20 µg/ml) in the absence 
or presence of LPS (1 µg/ml) for 2 days. The endocytic activity was assessed by 
measuring uptake of FITC-dextran. We found that HNK decreased the FITC-dextran 
uptake of not only immature DCs (Fig. 3A, 3C) but also LPS-activated DCs (Fig. 3B,
3C). In addition, we also assessed the ability of FITC-E. coli and lucifer yellow uptake. 
These results were in close agreement to the result of FITC-dextran uptake
(Supplementary Fig. S1). 
HNK decreases the production of TNF-Į, IL-1ȕ, IL-6, and IL-12p70 but 
increases the production of IL-10 and TGF-E1 by LPS-activated DCs 
DC-secreted cytokines play a pivotal role in the immune response and the interaction 
between DCs and T cells (Banchereau et al., 2000; Guermonprez et al., 2002). IL-12 
release by DCs drives the differentiation of naïve T cells toward the IFN-J-producing
Th1 phenotype (Gately et al., 1998). Proinflammatory cytokines such as TNF-D, IL-1E,
and IL-6 play a key role in inducing innate and acquired immune responses (Dinarello, 
1996). In this study, the cytokine levels in the supernatant of DCs cultured with HNK 
at various concentrations were measured by ELISA. The experimental results
indicated that HNK treatment did not alter the background levels of TNF-D, IL-1E,
IL-6, and IL-12p70 in the immature DC population, but it decreased the production of 
these cytokines by LPS-activated DCs in a dose-dependent manner (Fig. 4). In addition, 
we also examined whether HNK affects the production of anti-inflammatory cytokines, 
IL-10, and TGF-EOur experimental results showed that HNK treatment did not alter 
the background levels of IL-10 and TGF-E1 in the immature DC population, but
increased the production of these cytokines by LPS-activated DCs in a dose-dependent 
manner (Fig. 4). 
HNK suppresses the LPS-induced allogeneic T cell proliferation
The abovementioned results showed that HNK inhibited the expression of MHC-II and 
costimulatory molecules by LPS-activated DCs (Fig. 2). These surface molecules are 
involved in T-cell costimulation. Therefore, we further examined whether HNK affects 
LPS-induced DC-elicited T-cell proliferation. Immature DCs generated from human 
monocytes were treated with HNK at various concentrations (0, 5, 10, 15, and 20 
µg/ml) in the absence or presence of LPS (1 µg/ml) for 2 days. The DCs were then
cocultured with allogeneic T cells in an MLR assay. We found that HNK treatment of 
LPS-activated DCs significantly inhibited the proliferation of allogeneic T cells in the
MLR assay in a dose-dependent manner (Fig. 5). When immature DCs were treated
with HNK at various concentrations in the absence of LPS, the proliferation of the 
allogeneic T cells remained unaffected (data not shown). 
HNK alters the LPS-induced Th1 response toward the Th2 response
In the initial stage of the DC-T cell interaction, the cytokine microenvironment
plays a key role in Th cell differentiation toward the Th1 or Th2 cell types. Effector
Th1 cells predominantly secrete IFN-J and IL-2 and regulate cell-mediated immunity
against intracellular pathogens, whereas differentiated Th2 cells produce IL-4, IL-10, 
and IL-13 and promote antibody-mediated humoral immune responses (Abbas et al., 
1996). We investigated the T-cell differentiation induced by HNK-treated DCs. For
this, culture supernatants from allogeneic MLR experiments were analyzed by ELISA. 
The results showed that the HNK-treated immature DCs did not alter the background
levels of IFN-Ȗ, IL-4, IL-10, and IL-13 produced by T cells (Fig. 6A). However, IFN-Ȗ
production by T cells cultured with HNK-treated LPS-activated DCs was lower than
that by T cells cultured with DCs treated with LPS alone (Fig. 6A). Further, IL-4, 
IL-10, and IL-13 production by T cells cultured with HNK-treated LPS-activated DCs 
was greater than that by T cells cultured with DCs treated with LPS alone (Fig. 6A).
We further confirmed the cytokine produced by T cells cultured with HNK-treated 
LPS-activated DCs using intracellular staining assay. Our experimental results
indicated that culturing with HNK-treated LPS-activated DCs had a lower proportion 
of IFN-Jproducing T cells and had a greater proportion of IL-4 producing T cells than 
culturing with LPS-activated DCs alone (Fig. 6B). The proportions of IFN-Jor IL-4 
producing T cells had no significant change between HNK-treated immature DCs and 
immature DCs alone (data not shown). 
HNK inhibits the activation of NF-țB and MAPK in LPS-activated DCs 
LPS potently induces DC maturation and the production of proinflammatory cytokines 
by the activation of TLR4 through the NF-NB and MAPK signaling pathways 
(Dabbagh et al., 2002; Medzhitov, 2001). To examine whether the effects of HNK on 
LPS-induced DCs are associated with the NF-NB and MAPK signaling cascades, 
immature DCs were treated with LPS in the presence or absence of HNK. The 
phosphorylation levels of MAPK, including ERK1/2, JNK1/2, and p38, were analyzed 
by western blot analysis. The experimental results showed that HNK inhibits the 
phosphorylation levels of ERK1/2 significantly, p38 modestly, and JNK1/2 slightly on 
LPS-activated DCs (Fig. 7). We also found that HNK inhibits the phosphorylation of 
INBD significantly and IKKD modestly on LPS-activated DCs (Fig. 7). These results
indicate that HNK inhibits the activation of the MAPK and NF-NB signaling cascades 
in LPS-activated DCs.
Discussion
DCs play an important role in both the innate and adaptive immune responses. LPS can
trigger an acute inflammatory response, leading to a series of pathological events such
as septic shock (Martich et al., 1993). DCs are extremely sensitive to LPS and respond 
by releasing inflammatory mediators, maturing, and triggering an antigen-specific 
T-cell response (Lee et al., 2007; Rieser et al., 1998; Verhasselt et al., 1997). During 
DC maturation, the increased expression of MHC-II and costimulatory molecules
leads to T-cell response priming and proinflammatory cytokine secretion (Banchereau
et al., 2000; Banchereau and Steinman, 1998). Several characteristics of DCs change 
during DC maturation, e.g., CD83 expression is induced (Reddy et al., 1997), the 
expression of MHC-II and costimulatory molecules increases, and endocytic ability is
lost (Banchereau et al., 2000). 
Our experimental results indicate that HNK suppresses the LPS-induced 
expression of the CD11c, CD40, CD80, CD83, CD86, and MHC-II molecules by DCs, 
reduces the LPS-induced inflammatory cytokine (Th1-type cytokines) production 
while increasing anti-inflammatory cytokine (Th2- and regulatory-type cytokines)
production by DCs, suppresses the LPS-induced DC-elicited allogeneic T-cell 
proliferation, and Thus, HNK effectively prevents the LPS-induced inflammatory
response and DC maturation. Recent study also demonstrated that HNK treatment
decreased levels of proinflammatory cytokines and increased levels of the Th2- and 
regulatory-type cytokines IL-13, IL-10, and TGF-E in lung homogenates from mice in
acute and chronic asthma models (Munroe et al., 2010). In addition, HNK decreased
the mannose receptor-mediated endocytic ability of LPS-stimulated DCs (Fig. 3B).
Although endocytic ability is a characteristic of mature DCs, previous studies have 
shown that mannose receptor-mediated endocytosis does not affect the expression of 
MHC-II and costimulatory molecules, and antigen cross-presentation by mannose
receptor-deficient DCs (Burgdorf et al., 2006). The mannose receptor plays a
homeostatic role in the clearance of microorganisms and serum glycoproteins
(Burgdorf et al., 2006). Therefore, we suggest that HNK not only inhibits LPS-induced




 T helper cells can develop into four types of T cells: Th1, 
Th2, Th17, and regulatory T cells, based on the local cytokine milieu. The balance
between these four types of helper T cells is important for the regulation of immune
responses (Bettelli et al., 2006; Korn et al., 2009). Th1 cells are involved in cellular 
immunity, Th2 cells are involved in humoral immunity, Th17 cells are characterized as 
IL-17-producing CD4+ T cells and are critical for the initiation and maintenance of 
inflammation, and regulatory T cells are important in the maintenance of self-tolerance
and in regulation of inflammation (Saito, 2010). Previous studies have indicated that 
the balance between Th17 and regulatory T cells as a key factor that regulates helper
T-cell function relating to Th1/Th2 shift (Afzali et al., 2007; Bettelli et al., 2006). Our 
results indicate that HNK shifts the LPS-activated DC-driven Th1 response toward the
Th2 response which may associate with the balance between Th17 and regulatory T
cells. We further examined whether HNK-treated LPS-activated DCs affected the
balance between Th17 and regulatory T cells. Our experimental results showed that 
IL-17 production by T cells cultured with HNK-treated LPS-activated DCs was lower 
than that by T cells cultured with DCs treated with LPS alone (Supplementary Fig. S2).







 regulatory T cells than culturing with LPS-activated DCs alone 
(Supplementary Fig. S3). These results indicated that HNK shifting the LPS-activated
DC-driven Th1 response toward the Th2 response was not due to promoting regulatory 
T cells differentiation.
CD14 is essential for the LPS binding through the TLR4 receptor. Although
monocyte-derived DCs do not express CD14 (data not show) (Coutant et al., 1999; 
Yang et al., 2008), soluble CD14 can also mediate LPS binding on DCs, although with 
lower efficiency (Fenton and Golenbock, 1998; Scott and Billiar, 2008; Verhasselt et 
al., 1997). In addition, LPS uptake can also be mediated by the E2-integrin receptor,
independent of CD14 (Ammon et al., 2000; Fenton and Golenbock, 1998; Scott and 
Billiar, 2008). A question derived appears that HNK may compete with DCs for LPS
binding and uptake leading to the inhibition of LPS-induced DC maturation and the
subsequent inflammatory response. The results of the LPS-binding assay in this study 
showed that HNK does not affect LPS binding on DCs (Supplementary Fig. S4), which 
suggests that the inhibition of the LPS-induced inflammatory response by HNK is not 
due to the direct interaction between LPS and HNK. Moreover, we also examined
whether HNK affects sCD40L- and CPG ODN-induced DC maturation. Our results 
showed that HNK inhibits sCD40L- and CPG ODN-induced CD80 and MHC-II 
expression by DCs, indicating that HNK not only specifically affects LPS-induced DC 
maturation but also affects sCD40L- and CPG ODN-induced DC maturation
(Supplementary Fig. S5). In addition, our results showed that HNK decreases the 
expression of CD11c, MHC-II, and costimulatory molecules by immature DCs and
reduces their endocytic activity. Although these effects may be associated with DC 
maturation and the function of antigen uptake as well as antigen presentation, the 
precise mechanisms underlying these results remain unclear at present. 
The transcription factor NF-NB plays an important role in the regulation of multiple 
signaling pathways that control the activation of many immune cells (Kure et al.; Li
and Verma, 2002). Inhibition of NF-NB signaling pathway blocks LPS-mediated
maturation of DCs and up-regulation of MHC and costimulatory molecules expression
(Rescigno et al., 1998). LPS activates NF-NB via a cascade of events leading to the
activation of IKKs, which in turn phosphorylate INB and lead to the activation of
NF-NB-mediated gene expression (Karin and Ben-Neriah, 2000). In the present study,
we found that HNK treatment inhibited the phosphorylation of IKKD and INBD, which 
indicates that the NF-NB pathway may also be involved in the anti-inflammatory 
effects of HNK on LPS-activated human monocyte-derived DCs. A recent report 
indicated that HNK completely inhibits TNF-induced NF-NB activation in embryonic
kidney cells (A293) and T-cell leukemia (Jurkat) cells (Ahn et al., 2006). Taken 
together, the results suggest a pharmacological potential of HNK in NF-NB-associated
inflammatory disorders. Similar results were reported regarding the action of HNK on 
exercise-induced muscle damage in rats (Chiang et al., 2009). HNK was reported to
suppress high glucose content-induced cyclooxygenase (COX)-2 up-regulation and 
prostaglandin E2 production by human umbilical vein endothelial cells (Sheu et al., 
2008), the CD40- and LMP1-mediated inflammatory signaling pathway in mouse
B-cell activation (Munroe et al., 2007), and the production of IL-8, COX-2, and TNF-Į
by Propionibacterium acnes-activated THP-1 cells (Lee et al., 2005). In addition, the 
phosphorylation levels of ERK1/2, p38, and JNK1/2 were decreased in HNK-treated 
DCs, indicating the role of MAPK pathways in HNK-associated anti-inflammatory
reactions. MAPK activation is a downstream target of TLR4 signaling, which controls 
proinflammatory cytokine expression (Robinson and Cobb, 1997). Previous studies
have shown that MAPK activation is also important for regulation of the maturation
and survival of and cytokine secretion by DCs (Aiba et al., 2003; Arrighi et al., 2001; 
Nakagawa et al., 2004; Yu et al., 2004). Collectively, the findings indicate that HNK 
inhibits the LPS-induced maturation and inflammatory responses of DCs and that these 
changes are associated with the NF-NB and MAPK pathways. 
Natural products are a source of many medically beneficial drugs, and their
importance in preventing and treating diseases is increasingly being recognized. HNK 
has the potential to be a novel therapeutic agent. It was found to be safe and effective in 
treating inflammatory arthritis in a mouse model (Munroe et al., 2007) and as an 
anti-angiogenic agent in the treatment of cancer, both in vitro and in vivo (Bai et al., 
2003; Shigemura et al., 2007). HNK has poor water solubility and pharmacokinetics
that limit its clinical application in immune and cancer therapy (Liu et al., 2008). 
However, as a solution to overcoming these problems, it can be administered by 
encapsulation in liposomes (Wen et al., 2009) or micelles (Gong et al., 2009). 
In summary, to our knowledge, this investigation is the first to demonstrate the
anti-inflammatory activity of HNK in LPS-activated DCs. Our results show that HNK 
inhibits LPS-induced DC maturation, suppresses the LPS-induced overactive
inflammatory response, inhibits LPS-induced T-cells proliferation, alters the 
LPS-activated DC-driven Th1 response toward a Th2 response, and inhibits 
phosphorylation in the NF-NB and MAPK signaling cascades. The findings suggest 
that HNK inhibits the LPS-induced maturation and the inflammatory response of 
human monocyte-derived DCs via the MAPK and NF-NB signaling pathways. Finally, 
this study provides new insights into the anti-inflammatory properties of HNK and 
further supports the role of HNK as a candidate medicine for treating 
inflammation-related diseases.
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Legend for Figures
Fig. 1. HNK is not toxic at the experimental doses ( 20 µg/ml). Human immature DCs
were treated with HNK at various concentrations (0, 5, 10, 15, and 20 µg/ml) in the 
absence or presence of LPS (1 µg/ml) for 2 days. Cell viability was assessed by the 
MTT assay. Data are presented as mean ± SD from three independent experiments.
The statistical significance of the difference between two experimental measurements
was assessed by Student’s t-test and represented as follows: *, p < 0.05 and **, p <
0.01.
Fig. 2. Effects of HNK on the expression of the phenotypic characteristics of DCs. 
Expression of various surface markers on DCs was analyzed by flow cytometry after 
treatment with HNK at various concentrations (0 µg/ml (blue line), 10 µg/ml (green
line), or 20 µg/ml (red line)) in the absence or presence of LPS (1 µg/ml) for 2 days. 
The black line represents staining with the corresponding isotype control mAbs. The
results are representative of three independent experiments.
Fig. 3. Effects of HNK on the endocytic activity of DCs. Human immature DCs were
treated with HNK at various concentrations (0 µg/ml (blue line), 10 µg/ml (green line), 
or 20 µg/ml (red line)) of HNK in the (A) absence or (B) presence of LPS (1 µg/ml) for 
2 days. The cells were then incubated with FITC-dextran either at 37°C for 30 min or
at 4°C as a control (black line). The endocytic capacity was determined by assessing 
the endocytosis of FITC-dextran by flow cytometry. The results are representative of 
three independent experiments. (C) Data are presented as mean fluorescent intensity ± 
SD from three independent experiments. The statistical significance of the difference 
between two experimental measurements was assessed by Student’s t-test and
represented as follows: *, p < 0.05 and **, p < 0.01. 
Fig. 4. Effects of HNK on cytokine production by DCs. Human immature DCs were
treated with HNK at various concentrations (0, 5, 10, 15, and 20 µg/ml) in the absence 
or presence of LPS (1 µg/ml) for 2 days. The amounts of TNF-Į, IL-6, IL-12p70, 
IL-1EIL-10, and TGF-E1 in the culture supernatants were measured by ELISA. Data 
are presented as mean ± SD from three independent experiments. The statistical 
significance of the difference between two experimental measurements was assessed
by Student’s t-test and represented as follows: *, p < 0.05 and **, p < 0.01. 
Fig. 5. Effects of HNK on the induction of allogeneic T-cells proliferation by
LPS-activated DCs. Human immature DCs were treated with HNK at various
concentrations (0, 5, 10, 15, and 20 µg/ml) and LPS (1 µg/ml) for 2 days. The results of 
allogeneic T-cell proliferation were obtained with different DC:T cell ratios and
various dose responses. Allogeneic T-cell proliferation was measured by BrdU ELISA. 
Data are presented as mean ± SD from three independent experiments. The statistical 
significance of the difference between two experimental measurements was assessed
by Student’s t-test and represented as follows: *, p < 0.05 and **, p < 0.01. 
Fig. 6. Effects of HNK on the induction of allogeneic T-cells differentiation by DCs. 
(A) The amounts of IFN-Ȗ, IL-4, IL-10, and IL-13 in the cultured supernatants from 
allogeneic MLR experiments were measured by ELISA. (B) Analysis of intracellular 
cytokine production by T cells cocultured with LPS- or LPS/HNK-activated DCs. Data
are presented as mean ± SD from three independent experiments. The statistical 
significance of the difference between two experimental measurements was assessed
by Student’s t-test and represented as follows: *, p < 0.05 and **, p < 0.01. 
Fig. 7. Effects of HNK on the activation of the NF-țB and MAPK signaling cascades 
in LPS-activated DCs. Human immature DCs were treated with LPS (1 µg/ml) in the
absence or presence of HNK (20 µg/ml) for 0, 15, 60, 120, and 180 min. (A) The 
phosphorylation levels of ERK1/2, JNK1/2, p38, IKKĮ, and IțBĮ were measured by 
Western blot analysis. The figure is a representative of three independent experiments.
(B) The relative fold of phosphorylation activity each time was quantified using
AlphaImage software and normalized to that of the unphosphorylated form and 
compared to untreated control group (LPS alone). 
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